Javier Szwarcberg
CEO & DirectorDr. Javier Szwarcberg, M.D., M.P.H., is CEO & Director of Spruce Biosciences, Inc. from January 2022. Dr. Szwarcberg is an accomplished physician executive with many years of leadership experience in the biotechnology and pharmaceutical industries. He has an exceptionally rich skill set in clinical research and drug development, leading more than 22 clinical trials for a variety of drugs – including small molecules, peptides and biologics – with a proven track record of 4 successful drug approvals. Most recently, Dr. Szwarcberg served as the Group Vice President and Head of Program and Portfolio Development for BioMarin Pharmaceuticals from February 2020 to January 2022. Previously, he held positions as Senior Vice President, Head of Program and Portfolio Management at Ultragenyx Pharmaceutical from October 2017 to February 2020 and Vice President of R&D and Business Development at Horizon Pharma. He is currently a scientific advisor to Abalone Bio. Dr. Szwarcberg received his MPH from the Harvard School of Public Health and his M.D. from Universidad de Buenos Aires School of Medicine. From October 2016 to October 2017, Dr. Szwarcberg served as Vice President of Clinical Development and Business Development for Horizon Pharma plc, a biopharmaceutical company.
Positions
- Company NameSpruce Biosciences, Inc.Stock CodeSPRBPositionCEO & DirectorColleagues
- MGMichael G. GreyExecutive Chairman
- SMSamir M. GharibPresident & CFO
- EJEric JordanVice President of Marketing
- BGBruno GagnonSenior Vice President of Clinical Development Operations
- CVCamilla V. SimpsonIndependent Director
- DKDaniel K. SpiegelmanIndependent Director
- PBPercival Barretto-KoIndependent Director
